The FDA Didn’t Warn Against AI. It Warned Against Undefended AI

When an FDA warning letter mentions artificial intelligence, it is easy to assume the agency is pushing back against AI itself. That was the reaction to the FDA’s April 2026 warning letter to Purolea Cosmetics Lab. But that is not what the letter actually says.

The FDA did not criticize the use of AI. It criticized the lack of appropriate oversight, scientific judgment, and quality controls surrounding its use. The company was cited for significant CGMP failures, including inadequate testing, weak supplier qualification, and poor process validation. The FDA also made it clear that AI-generated documents and recommendations must still be reviewed and approved by qualified personnel before they can be used in regulated activities.

This distinction is important because it changes how life sciences organizations should think about AI adoption. The real question is not whether AI is allowed. The question is whether its use can be defended.

Defensible AI means using AI within a controlled, risk-based framework. Organizations should clearly define the AI’s intended use, ensure subject matter experts review its outputs, maintain complete traceability, and preserve evidence that demonstrates why AI-assisted decisions were accepted. Human review is not simply an approval step. It is part of a structured quality process supported by documentation, governance, and accountability.

As AI becomes more common across validation, manufacturing, and quality operations, regulators are also expanding their guidance. Rather than discouraging AI, they are encouraging organizations to use it responsibly through proper governance, lifecycle management, and risk-based decision making.

For validation and quality teams, this means shifting the conversation from productivity to defensibility. AI can accelerate document creation and support decision making, but it cannot replace scientific expertise, quality oversight, or regulatory responsibility. Organizations that build controlled and transparent AI workflows will be far better prepared for inspections and long-term compliance.

If you would like to explore this topic in greater detail, including the FDA warning letter and the regulatory expectations surrounding AI governance, visit the full article through the link.